---
title: Accelerating Vaccine Development By Innovative Purification Solutions and State of the Art Quality Testing
---

[![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

## ![New-ATE-Logo2019](https://bpi.bioprocessintl.com/hs-fs/hubfs/New-ATE-Logo2019.png?width=700&name=New-ATE-Logo2019.png)

### **Accelerating Vaccine Development By Innovative Purification Solutions and State of the Art Quality Testing**

 Please watch this on-demand Ask the Expert webcast.

Just follow**[this link](https://bioprocessintl.com/sponsored-content/accelerating-vaccine-development-by-innovative-purification-solutions-and-state-of-the-art-quality-testing/)**to watch the webcast now.

## **![florian-sirat](https://bpi.bioprocessintl.com/hs-fs/hubfs/florian-sirat.jpg?width=200&name=florian-sirat.jpg)**Presenters:

**Sirat Sikka and Florian Durst**

Field Application Scientists (Purification and Pharma Analytics), Thermo Fisher Scientific

 

Sirat has an MS in biomanufacturing from North Carolina State University, USA. Her thesis focused on understanding protein–protein interactions. She has also worked at the Institute of Genetics and Genetic Diseases R&D in India after completing her bachelor’s in biotechnology. She worked for five years at the GlaxoSmithKline Vaccines R&D center (USA) as a downstream scientist. Her responsibilities included process development and optimization for recombinant-protein and nucleic-acid vaccines. Sirat is currently working at Thermo Fisher Scientific as a field application scientist for POROS and CaptureSelect™ purification products.

Florian is a biochemist by training. He graduated from the Institute of Biophysical Chemistry of the Goethe University in Frankfurt, Germany. As a PhD student he developed a strong background in protein chemistry, structural biology, and biophysical methods. After his graduation he worked as a lecturer at Goethe University focusing on protein characterization, protein interaction, and scientific/technical writing for several years. In 2018 he joined Thermo Fisher Scientific as a field application specialist for Pharma Analytics. 

 

## About this event:

#### On Demand

#### Duration: 30 minutes

The emergence of new diseases and infections has entailed the need for rapid and efficient development of safe and efficacious vaccines. Additionally, no effective vaccines currently exist for long-known pandemic diseases such as HIV or malaria. To address the challenges the vaccine industry faces, new vaccine modalities such as viral vectors, recombinant protein subunits, and nucleic acids are being researched and developed, with each vaccine production process being unique and having its own challenges and regulatory impediments.

 

The growing diversity of vaccines calls for development and manufacturing solutions tailored towards each vaccine molecule type. This is valid specifically for downstream processes as each molecule requires its own unique purification strategy. In conjunction, regulatory agencies expect safety and purity testing for a variety of analytes throughout the entire production process. Implementation and use of these assays are often time consuming and require significant resources and efforts.

 

During this webinar we will present innovative chromatography solutions that can help in improving the downstream processes of different vaccine types. In addition, we will address regulatory requirements for safety and purity testing during the vaccine production process and discuss the benefits of implementing automated systems to save time and demonstrate product quality and safety. 

 

**Learning points**:

- Understand the benefits of implementing affinity chromatography into a vaccine production process.
- Find out how Thermo Scientific POROS™ chromatography resins help to maximize efficiency of the downstream process of large molecules and vaccine modalities such as virus-like particles, viral vectors, proteins, and mRNA.
- Learn more on ways to confirm purity using industry-recognized and regulatory-accepted real-time PCR residual host cell DNA solutions, such as resDNASEQ. 
- Understand mycoplasma testing regulatory requirements for lot release and how the MycoSEQ Rapid mycoplasma detection system has been validated and accepted by regulators in multiple modalities.

-  

-  

©2015 BioProcess International All Rights reserved